ClassID:

92857

C07C235/78 - CPC Classification

Classification description:

Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings

Recent Application in this class:
#1
20260008792
2026-01-08

PROCESSES AND COMPOUNDS

#2
20250145561
2025-05-08

4-SUBSTITUTED-PHENYL ACETAMIDES AND ARYLUREAS AS AGONISTS FOR THE ORPHAN RECEPTOR GPR88

#3
20250099407
2025-03-27

2-AMINO BENZOPHENONE DERIVATIVES FOR TARGETED FERROPTOSIS INDUCTION IN CANCER THERAPY

#4
20250051266
2025-02-13

Novel GLV-Phenolamide: Biosynthesis and Function in Protecting Plants from Herbivore Attack

#5
20240360068
2024-10-31

CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES

#6
20240317832
2024-09-26

UNNATURAL AMINO ACID, AND USE THEREOF, RECOMBINANT PROTEIN CONTAINING SAME, AND RECOMBINANT PROTEIN CONJUGATE

#7
20240287000
2024-08-29

ACETYLSALICYLIC ACID DERIVATIVE AND APPLICATION THEREOF

#8
20240018110
2024-01-18

RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN

#9
20230364029
2023-11-16

POLYMORPHIC FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE

#10
20230265041
2023-08-24

CURCUMIN ANALOGUES AS ZINC CHELATORS AND TEHIR USES

#11
20220380298
2022-12-01

Inhibitors of the n-terminal domain of the androgen receptor

#12
20220265578
2022-08-25

Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

#13
20220213080
2022-07-07

Piperlongumine-based compound and immuno regulator comprising the same

#14
20220162233
2022-05-26

PROCESSES AND COMPOUNDS

#15
20220017462
2022-01-20

ORTHO-PHTHALALDEHYDE CONTAINING LINKERS AND USE FOR PREPARATION OF ANTIBODY-DRUG CONJUGATE

#16
20210387950
2021-12-16

Acetylsalicylic acid derivative and application thereof

#17
20210179542
2021-06-17

4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

#18
20210139435
2021-05-13

PROSTAGLANDIN ANALOGS AND USES THEREOF

#19
20210130301
2021-05-06

Compositions for the treatment of pulmonary fibrosis

#20
20210094907
2021-04-01

Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy

#21
20210053905
2021-02-25

Curcumin analogues as zinc chelators and their uses

#22
20210015765
2021-01-21

Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

#23
20200215001
2020-07-09

Compounds, compositions and methods for treating oxidative DNA damage disorders

#24
20200079721
2020-03-12

Sacubitril intermediate and preparation method thereof

#25
20190382335
2019-12-19

Inhibitors of the N-terminal domain of the androgen receptor

#26
20190365671
2019-12-05

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS

#27
20190307706
2019-10-10

Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

#28
20190270712
2019-09-05

Compositions for the treatment of pulmonary fibrosis

#29
20190270699
2019-09-05

4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

#30
20190185694
2019-06-20

Curable gellant ink

#31
20180319828
2018-11-08

Preparation method for tedizolid, tedizolid intermediate, and preparation method therefor

#32
20180312476
2018-11-01

Method for preparing oxazolidinone intermediate

#33
20180194718
2018-07-12

Neprilysin inhibitors

#34
20180133175
2018-05-17

Quinone compounds for treating APE1 mediated diseases

#35
20180118661
2018-05-03

Compounds and methods for the treatment of neurodegenerative diseases

#36
20180022693
2018-01-25

Enamine compounds for absorbance of electromagnetic energy

#37
20180000749
2018-01-04

Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

#38
20170360740
2017-12-21

Histone deacetylase inhibitors

#39
20170360037
2017-12-21

3′-substituted-abscisic acid derivatives

#40
20170327459
2017-11-16

Neprilysin inhibitors

#41
20170313649
2017-11-02

4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

#42
20170304222
2017-10-26

Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders

#43
20170158605
2017-06-08

Curcumin analogues as zinc chelators and their uses

#44
20170015619
2017-01-19

Neprilysin inhibitors

#45
20160340347
2016-11-24

THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION

#46
20160280636
2016-09-29

Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto

#47
20160264539
2016-09-15

Compounds with (1E, 6E)-1,7-Bis-(3,4-dimethoxyphenyl)-4-4-distributed-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

#48
20160143874
2016-05-26

Histone deacetylase inhibitors

#49
20160137592
2016-05-19

Compounds advantageous in the treatment of central nervous system diseases and disorders

#50
20160115141
2016-04-28

CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS

#51
20160075638
2016-03-17

4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

#52
20160045461
2016-02-18

Quinone compounds for treating Ape1 mediated diseases

#53
20160031795
2016-02-04

Curcumin analogues as zinc chelators and their uses

#54
20160007598
2016-01-14

3′-substituted-abscisic acid derivatives

#55
20150376128
2015-12-31

Neprilysin inhibitors

#56
20150368264
2015-12-24

SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS

#57
20150243996
2015-08-27

Electrical conductive polymer binder for Si alloy materials

#58
20150225333
2015-08-13

Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto

#59
20150190351
2015-07-09

Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyI)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

#60
20150175586
2015-06-25

Therapeutic agents for ocular hypertension

#61
20150166469
2015-06-18

Neprilysin inhibitors

#62
20150111969
2015-04-23

J-series prostaglandin-ethanolamides as novel therapeutics

#63
20150104429
2015-04-16

Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression

#64
20150051419
2015-02-19

Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium

#65
20150038581
2015-02-05

Histone deacetylase inhibitors

#66
20150018355
2015-01-15

Compounds and methods for treating leukemia

#67
20150011627
2015-01-08

Triterpenoids and compositions containing the same

#68
20140350032
2014-11-27

Propenoate derivatives of betulin

#69
20140336235
2014-11-13

Substituted biaryl alkyl amides

#70
20140329860
2014-11-06

2-substituted--quinone derivatives for treatment of oxidative stress diseases

#71
20140296240
2014-10-02

SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS

#72
20140296183
2014-10-02

AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES

#73
20140275088
2014-09-18

Small molecule malarial Aldolase-TRAP enhancers and glideosome inhibitors

#74
20140213813
2014-07-31

Haloalkylmethyleneoxyphenyl-substituted ketoenols

#75
20140213620
2014-07-31

HISTONE DEACETYLASE INHIBITORS

#76
20140128398
2014-05-08

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS

#77
20140094464
2014-04-03

Quinone compounds for treating Ape1 mediated diseases

#78
20140031577
2014-01-30

Haloalkylmethyleneoxyphenyl-substituted ketoenols

#79
20140024852
2014-01-23

Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto

#80
20130338160
2013-12-19

Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

#81
20130303607
2013-11-14

Triterpenoids and compositions containing the same

#82
20130289034
2013-10-31

4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

#83
20130281705
2013-10-24

Compounds for the treatment of metabolic disorders

#84
20130261121
2013-10-03

Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof

#85
20130123356
2013-05-16

Modulator

#86
20130109710
2013-05-02

SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF

#87
20130079514
2013-03-28

Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells

#88
20120316169
2012-12-13

2-ARYL-PROPIONAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

#89
20120302534
2012-11-29

DERIVATIVES OF BETULIN

#90
20120270877
2012-10-25

IRE-1α inhibitors

#91
20120232303
2012-09-13

Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto

#92
20120122934
2012-05-17

4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

#93
20120095051
2012-04-19

Curcumin analogues as zinc chelators and their uses

#94
20120093742
2012-04-19

Compounds

#95
20120053346
2012-03-01

Pyrimidine carboxamide derivatives

#96
20110311444
2011-12-22

Imaging diagnostic agent and extracorporeal diagnostic agent for incurable neurological diseases

#97
20110306668
2011-12-15

Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid

#98
20110124679
2011-05-26

2-substituted--quinone derivatives for treatment of oxidative stress diseases

#99
20110086868
2011-04-14

SPECIFIC INHIBITORS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS

#100
20100311593
2010-12-09

Haloalkylmethyleneoxyphenyl-substituted ketoenols

#101
20100305131
2010-12-02

Substituted aminopropionic derivatives as neprilysin inhibitors

#102
20100279963
2010-11-04

DICARBONYL DERIVATIVES AND METHODS OF USE

#103
20100160327
2010-06-24

Modified malonate derivatives

#104
20100144879
2010-06-10

Antibiotic compound

#105
20100144876
2010-06-10

Modulator

#106
20100099682
2010-04-22

ACETYLENE DERIVATIVES

#107
20100087523
2010-04-08

Rupestonic acid derivatives and use thereof

#108
20100076034
2010-03-25

2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them

#109
20100056588
2010-03-04

Histone deacetylase inhibitors

#110
20100036163
2010-02-11

Process for the synthesis of agomelatine

#111
20090291904
2009-11-26

CHEMICAL DERIVATIVES OF JASMONATE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

#112
20090281154
2009-11-12

Ophthalmic Compositions for Treating Ocular Hypertension

#113
20090258884
2009-10-15

Substituted amides

#114
20090247522
2009-10-01

Hsp90 family protein inhibitors

#115
20090247472
2009-10-01

TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS

#116
20090186900
2009-07-23

COMPOUND

#117
20090181971
2009-07-16

Inhibitors of Histone Deacetylase

#118
20090170908
2009-07-02

Spiro compounds and pharmaceutical use thereof

#119
20090137530
2009-05-28

Amine compound and use thereof for medical purposes

#120
20090118257
2009-05-07

4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

#121
20090048258
2009-02-19

Amide Compound

#122
20090042883
2009-02-12

ANTITUMOR AGENT

#123
20080319065
2008-12-25

Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release

#124
20080312293
2008-12-18

2-arylpropionic acid derivatives and pharmaceutical compositions containing them

#125
20080221018
2008-09-11

Crystalline solid and amorphous forms of (−)- halofenate and methods related thereto

#126
20080214673
2008-09-04

Acetylene derivatives

#127
20080213347
2008-09-04

Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof

#128
20080171692
2008-07-17

Substituted pyridyoxy amides

#129
20080146586
2008-06-19

Dicarbonyl derivatives and methods of use

#130
20080139585
2008-06-12

Specific inhibitors for vascular endothelial growth factor receptors

#131
20080114062
2008-05-15

Modulator

#132
20080045522
2008-02-21

OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS

#133
20080027229
2008-01-31

Compounds for the treatment of metabolic disorders

#134
20080021109
2008-01-24

Compounds for the treatment of metabolic disorders

#135
20080015209
2008-01-17

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

#136
20070265323
2007-11-15

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

#137
20070265322
2007-11-15

Method for the treatment of metabolic disorders

#138
20070249719
2007-10-25

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

#139
20070249696
2007-10-25

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

#140
20070244172
2007-10-18

Method for the treatment of metabolic disorders

#141
20070244171
2007-10-18

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

#142
20070244141
2007-10-18

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

#143
20070105958
2007-05-10

Methods for the treatment of metabolic disorders such as diabetes

#144
20070066851
2007-03-22

Palladium-catalyzed carbon-carbon bond forming reactions

#145
20070066586
2007-03-22

Aniline derivatives

#146
20070032532
2007-02-08

Hsp90 family protein inhibitors

#147
20070003680
2007-01-04

Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers

#148
20060235074
2006-10-19

Matrix metalloproteinase inhibitors

#149
20050256333
2005-11-17

Compounds for the treatment of metabolic disorders

#150
20050250819
2005-11-10

Inhibitors of bacterial type III protein secretion systems

#151
20050234131
2005-10-20

Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof

#152
20050234061
2005-10-20

Substituted amides

#153
20050090555
2005-04-28

Compound for the treatment of metabolic disorders

#154
20050080067
2005-04-14

Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells

#155
20050049313
2005-03-03

Electron mediator, electron mediator immobilized electrode, and biofuel cell using the electrode

#156
20050020450
2005-01-27

α-oxygenated or α-thiolated carboxylic acid phenethylamide derivatives

#157
20050004115
2005-01-06

Compounds for the treatment of metabolic disorders